276 related articles for article (PubMed ID: 17164332)
1. The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma.
Podar K; Tonon G; Sattler M; Tai YT; Legouill S; Yasui H; Ishitsuka K; Kumar S; Kumar R; Pandite LN; Hideshima T; Chauhan D; Anderson KC
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19478-83. PubMed ID: 17164332
[TBL] [Abstract][Full Text] [Related]
2. Anti-angiogenic effects of the receptor tyrosine kinase inhibitor, pazopanib, on choroidal neovascularization in rats.
Yafai Y; Yang XM; Niemeyer M; Nishiwaki A; Lange J; Wiedemann P; King AG; Yasukawa T; Eichler W
Eur J Pharmacol; 2011 Sep; 666(1-3):12-8. PubMed ID: 21620822
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
4. The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
Paesler J; Gehrke I; Gandhirajan RK; Filipovich A; Hertweck M; Erdfelder F; Uhrmacher S; Poll-Wolbeck SJ; Hallek M; Kreuzer KA
Clin Cancer Res; 2010 Jul; 16(13):3390-8. PubMed ID: 20570929
[TBL] [Abstract][Full Text] [Related]
5. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Lin B; Podar K; Gupta D; Tai YT; Li S; Weller E; Hideshima T; Lentzsch S; Davies F; Li C; Weisberg E; Schlossman RL; Richardson PG; Griffin JD; Wood J; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):5019-26. PubMed ID: 12208756
[TBL] [Abstract][Full Text] [Related]
6. GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment.
Podar K; Catley LP; Tai YT; Shringarpure R; Carvalho P; Hayashi T; Burger R; Schlossman RL; Richardson PG; Pandite LN; Kumar R; Hideshima T; Chauhan D; Anderson KC
Blood; 2004 May; 103(9):3474-9. PubMed ID: 14644994
[TBL] [Abstract][Full Text] [Related]
7. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
8. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.
Roccaro AM; Hideshima T; Raje N; Kumar S; Ishitsuka K; Yasui H; Shiraishi N; Ribatti D; Nico B; Vacca A; Dammacco F; Richardson PG; Anderson KC
Cancer Res; 2006 Jan; 66(1):184-91. PubMed ID: 16397231
[TBL] [Abstract][Full Text] [Related]
9. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.
Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y
Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174
[TBL] [Abstract][Full Text] [Related]
10. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms.
Huh JI; Calvo A; Stafford J; Cheung M; Kumar R; Philp D; Kleinman HK; Green JE
Oncogene; 2005 Jan; 24(5):790-800. PubMed ID: 15592523
[TBL] [Abstract][Full Text] [Related]
12. miR-15a and miR-16 affect the angiogenesis of multiple myeloma by targeting VEGF.
Sun CY; She XM; Qin Y; Chu ZB; Chen L; Ai LS; Zhang L; Hu Y
Carcinogenesis; 2013 Feb; 34(2):426-35. PubMed ID: 23104180
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
14. Targeting of integrin-linked kinase with small interfering RNA inhibits VEGF-induced angiogenesis in retinal endothelial cells.
Xie W; Zhao M; Zhou W; Guo L; Huang L; Yu W; Li X
Ophthalmic Res; 2013; 49(3):139-49. PubMed ID: 23258222
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor beta receptor I kinase inhibitor down-regulates cytokine secretion and multiple myeloma cell growth in the bone marrow microenvironment.
Hayashi T; Hideshima T; Nguyen AN; Munoz O; Podar K; Hamasaki M; Ishitsuka K; Yasui H; Richardson P; Chakravarty S; Murphy A; Chauhan D; Higgins LS; Anderson KC
Clin Cancer Res; 2004 Nov; 10(22):7540-6. PubMed ID: 15569984
[TBL] [Abstract][Full Text] [Related]
16. Lentiviral shRNA silencing of BDNF inhibits in vivo multiple myeloma growth and angiogenesis via down-regulated stroma-derived VEGF expression in the bone marrow milieu.
Zhang L; Hu Y; Sun CY; Li J; Guo T; Huang J; Chu ZB
Cancer Sci; 2010 May; 101(5):1117-24. PubMed ID: 20331634
[TBL] [Abstract][Full Text] [Related]
17. CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment.
Wang SW; Liu SC; Sun HL; Huang TY; Chan CH; Yang CY; Yeh HI; Huang YL; Chou WY; Lin YM; Tang CH
Carcinogenesis; 2015 Jan; 36(1):104-14. PubMed ID: 25330803
[TBL] [Abstract][Full Text] [Related]
18. The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications.
Podar K; Zimmerhackl A; Fulciniti M; Tonon G; Hainz U; Tai YT; Vallet S; Halama N; Jäger D; Olson DL; Sattler M; Chauhan D; Anderson KC
Br J Haematol; 2011 Nov; 155(4):438-48. PubMed ID: 21923653
[TBL] [Abstract][Full Text] [Related]
19. Vesnarinone inhibits angiogenesis and tumorigenicity of human oral squamous cell carcinoma cells by suppressing the expression of vascular endothelial growth factor and interleukin-8.
Harada K; Supriatno ; Yoshida H; Sato M
Int J Oncol; 2005 Dec; 27(6):1489-97. PubMed ID: 16273203
[TBL] [Abstract][Full Text] [Related]
20. A new chemical inhibitor of angiogenesis and tumorigenesis that targets the VEGF signaling pathway upstream of Ras.
Desroches-Castan A; Quélard D; Demeunynck M; Constant JF; Dong C; Keramidas M; Coll JL; Barette C; Lafanechère L; Feige JJ
Oncotarget; 2015 Mar; 6(7):5382-411. PubMed ID: 25742784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
